In this study, 191 cases with colorectal liver metastases were included who received bevacizumab containing chemotherapy. 50 patients were resectable and defined as surgical group, and 141 were inoperable and defined as medical group. The surgical group was used to describe the morphological changes which are induced by bevacizumab containing chemotherapy independent of change in tumor size, and to define new tumor response criteria, and to compare the morphologic response with the response evaluated with the RECIST criteria and with the pathology response on surgical specimen.The medical group was used to validate and correlate these proposed criteria with survival and tumor markers, and to describe the patterns of early recurrence after initial response.Thesemorphologicalcriteriathatwereidentifiable onsinglephase CECT correlated with pathologic response as well as overall survival and progression free survival, whereas RECIST does not.The lack of morphologic response is more specific for poor pathologic response than SD or PD by RECIST.